Allen Discovery Center announced your life history is written in your cells’ mutations
On Apr. 13, 2020, the Allen Discovery Center for Human Brain Evolution announced a study that traced developmental…
NIAID trial of Anti-CD14 antibody to treat COVID-19 respiratory disease began
On Apr. 13, 2021, a clinical trial testing the safety and efficacy of an investigational monoclonal antibody for…
Study linked structural brain changes to behavioral problems in children who snore
On Apr. 13, 2021, a large study of children has uncovered evidence that behavioral problems in children who…
Cardinal Health awarded Strategic National Stockpile contract for PPE storage and distribution
On Apr. 13, 2021, Cardinal Health was awarded a $57.8 million contract, including options that if exercised by…
Joint CDC and FDA statement on Johnson & Johnson COVID-19 vaccine
As of Apr. 12, 2021, more than 6.8 million doses of the Johnson & Johnson (Janssen) vaccine were…
FDA recommended pause in use of J&J vaccine after adverse events reported
On Apr. 13, 2021, the FDA and CDC announced that they were are reviewing data involving six reported…
Positive topline data showed Fostamatinib met primary endpoint of safety in phase 2 clinical trial in hospitalized COVID-19 patients
On Apr. 13, 2021, Rigel Pharma announced the completion of patient enrollment in a multi-center Phase 2 clinical…
Moderna updated clinical and supply on COVID-19 vaccine program
On Apr. 13, 2021, Moderna announced that new results from a preclinical study of the Company’s COVID-19 variant-specific…
Health Canada Issued Resverlogix authorization to begin immediate clinical studies of apabetalone for COVID-19
On Apr. 12, 2021, Resverlogix announced that it had successfully received its desired ‘No Objection Letter’ from Health…
Phase III trial showed subcutaneous administration of investigational antibody cocktail reduced risk of symptomatic COVID-19 infections by 81%
On Apr. 12, 2021, Roche confirmed positive results from the phase III REGN-COV 2069 trial assessing the ability…
Asthma drug budesonide shortened recovery time in non-hospitalised patients with COVID-19
On Apr. 12, 2021, Oxford University reported that early treatment with inhaled budesonide shortened recovery time by a…
FDA authorized new high-throughput, automated system for leading COVID-19 test
On Apr. 12, 2021, Thermo Fisher Scientific announced that the U.S. Food and Drug Administration (FDA) had granted…
The Priestley Medal was awarded to Paul Alivisatos
On Apr. 9, 2021, the American Chemical Society awarded The Priestley Medal to Paul Alivisatos “to recognize distinguished…
Biotechnology | COVID-19 | Life Science News | NIH | Therapeutics | Vaccine
NIH COVID-19 treatment guidelines strongly recommended Use of REGEN-COV in high risk outpatients
On Apr. 9, 2021, Regeneron announced that newly updated National Institutes of Health (NIH) COVID-19 treatment guidelines strongly…
Pfizer and BioNTech requested regulatory agencies expand Emergency Use of COVID-19 vaccine to adolescents
On Apr. 9, 2021, Pfizer announced they had requested amendments to the U.S. Emergency Use Authorization (EUA) of…
Antiviral drug Favipiravir investigated as a possible COVID-19 treatment for at-home recovery in PRINCIPLE trial
On Apr. 8, 2021, Oxford University announced that favipiravir was to be investigated in the UK as part…
ImmunityBio announced single prime hAd5 COVID-19 vaccination induced 10-fold increase in T cell response
On Apr. 8, 2021, ImmunityBio reported initial data indicating that a single subcutaneous injection of the companyï¾’s COVID-19…
Lilly and Incyte phase 3 COV-BARRIER study of baricitinib in COVID-19 patients did not meet endpoint
On Apr. 8, 2021, Eli Lilly and Incyte announced results of COV-BARRIER, a Phase 3 study evaluating baricitinib…
NIH began study of allergic reactions to Moderna, Pfizer-BioNTech COVID-19 vaccines
On Apr. 7, 2021, the National Institutes of Health (NIH) announced that a clinical trial was underway to…
WHO Global Advisory Committee on Vaccine Safety reported on AstraZeneca COVID-19 vaccine
On Apr. 7, 2021, the COVID-19 subcommittee of the WHO Global Advisory Committee on Vaccine Safety (GACVS) announed…
AIM ImmunoTech announced positive data in phase 1 study Investigating intranasal administration of Ampligen as potential treatment for COVID-19
On Apr. 7, 2021, AIM ImmunoTech announced that it had completed dosing of Cohort 1 in a Phase…
Moderna announced publication of antibody persistence data of its COVID-19 vaccine in the NEJM
On Apr. 7, 2021, Moderna announced publication of antibody persistence data out to 6 months following the second…
McGill University researchers developed innovative tough gel sheathed (TGS) sutures inspired by the human tendon
On Apr. 7, 2021, McGill University researchers announced that they had developed an innovative tough gel sheathed (TGS)…
CDC awarded $3 billion to expand COVID-19 vaccine programs
On Apr. 7, 2021, the Centers for Disease Control and Prevention (CDC) announced it had awarded $3 billion…
Moderna and Catalent announced long-term strategic collaboration for vial filling of COVID-19 vaccine
On Apr. 6, 2021, Moderna and Catalent announced the expansion of their strategic collaboration to dedicate a new…
Nearly 80 percent of teachers, school staff, and childcare workers received at least one shot of COVID-19 vaccine
On Apr. 6, 2021, the Centers for Disease Control and Prevention (CDC) reported that nearly 80 percent of…
The FDA issued an EUA to Symbiotica for the COVID-19 self-collected antibody test system
On Apr. 5, 2021, the FDA issued an Emergency Use Authorization (EUA) to Symbiotica for the COVID-19 Self-Collected…
Anixa Biosciences and OntoChem entered next stage of development for Covid-19 therapeutic
On Apr. 5, 2021, Anixa Biosciences announced that based on Proof of Concept animal study results, it was…
Positive phase 1/2 results reported for Valneva’s inactivated COVID-19 vaccine candidate using CpG 1018ï¾™ adjuvant
On Apr. 5, 2021, Dynavax Technologies announced that Valneva had reported positive initial results for Part A of…
Innovation Pharma announced increased dosing in phase 2 clinical trial of Brilacidin in COVID-19 patients
On Apr. 5, 2021, Innovation Pharmaceuticals announced that an independent Data Monitoring Committee (DMC) completed its scheduled review…